三维适形调强放疗联合奈达铂对宫颈癌患者治疗效果的影响

Effects of intensity-modulated radiotherapy combined with nedaplatin on the treatment of patients with cervical cancer

目的:探讨三维适形调强放疗(IMRT)联合奈达铂治疗宫颈癌的效果。方法:选取84例宫颈癌患者,按照随机数字表法将其分为两组,每组42例。对照组采用IMRT,研究组在对照组基础上联合奈达铂。比较两组总有效率、疾病控制率、肿瘤标志物水平、miRNA水平、不良反应及远期治疗效果。结果:研究组总有效率83.33%高于对照组64.29%,差异有统计学意义(P<0.05);研究组疾病控制率92.86%高于对照组76.19%(P<0.05);治疗后,研究组血清肿瘤标志物AFP、CK19、CA125、Chemerin的水平均低于对照组(P<0.05);治疗后,血清中miR-130b-5p、miR-142-5p的水平均低于对照组(P<0.05);两组治疗期间不良反应发生率及治疗后1年生存率比较,差异均无统计学意义(P>0.05);随访1年,研究组远处转移率、局部复发率均低于对照组(P<0.05)。结论:IMRT联合奈达铂治疗宫颈癌效果显著,能降低患者血清肿瘤标志物水平,调控miRNA表达,减少复发转移风险。

Objective:To investigate the effects of intensity-modulated radiotherapy(IMRT)combined with nedaplatin in patients with cervical cancer.Methods:84 patients with cervical cancer were randomized into two groups,each with 42 patients.The control group received IMRT,while the study group were treated with IMRT combined with nedaplatin.The total effective rate,disease control rate,levels of tumor marker and miRNA,adverse reactions and long-term efficacy were compared between the two groups.Results:The total effective rate of the study group was 83.33%,higher than 64.29%of the control group,the difference was statistically significant(P<0.05);the disease control rate was 92.86%in the study group,higher than 71.69%in the control group(P<0.05);after treatment,levels of serum tumor marker AFP,CK19,CA125,chemer in of the study group were lower than those of the control group(P<0.05);after treatment,levels of serum miR-130b-5p and miR-142-5p of the study group averaging lower than those of the control group(P<0.05);There was no significant difference in the incidence of adverse reactions during treatment and one-year survival rate after treatment between the two groups(P>0.05);and the distant metastasis and local recurrence rate in the study group was lower than that in the control group for one-year follow-up(P<0.05).Conclusion:IMRT combined with nedaplatin has gained remarkable effect on patients with cervical cancer,which can lower the serum tumor marker level,regulate miRNA expression and reduce the risk of recurrence and metastasis in patients.